Drive Impactful Science from Bench to Market
Learn how Certara drives impactful science.
CertaraJune 14, 2021
Your First Choice in Complex Biologics Drug Development
The pharmaceutical has made massive investments in complex biologics, a drug class that includes oligonucleotide…
CertaraJune 1, 2021
The Wizard of Oligos: There’s no place like having a successful drug development program!
Oligonucleotide therapies— nucleic acid polymers with the potential to treat or manage a wide range…
CertaraApril 30, 2021
Certara (CERT) – Accelerating Medicines with Biosimulation
As seen on CNBC** Certara is the global leader in biosimulation, a powerful and proven…
CertaraApril 27, 2021
Part 3: Oligonucleotide therapeutic development: Clinical pharmacology considerations
In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including…
CertaraApril 21, 2021
Part 2: Oligonucleotide therapeutic development: Pre-clinical and translational considerations
In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including…
CertaraApril 21, 2021
Part 1: What are oligonucleotide therapeutics, and how do they work?
In the last few years, the pharmaceutical industry has invested in developing Complex Biologics including…
CertaraApril 21, 2021
Predicting the Effect of the Dulaglutide-Mediated Gastric Emptying Delay on Drug Exposure
The European Medicines Agency (EMA) recently approved dulaglutide (Trulicity®) at higher doses (3 mg and…
CertaraApril 1, 2021
Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence
The extent of cross-protection provided by currently licensed bivalent and quadrivalent HPV vaccines versus direct…
CertaraMarch 18, 2021
Sealing Pharma Commercialization Deals: Creating Optimal Value for Investors
It is crucial for biotech developers to engage in early commercial market assessment to generate…
CertaraMarch 5, 2021
